NeuroChronix
We are developing novel, non-opioid therepeutics for the management of chronic pain.
| Date | Investors | Amount | Round |
|---|---|---|---|
$20.0k | Angel | ||
| Total Funding | 000k | ||
Related Content
NeuroChronix, founded in 2022, is a developer of novel, non-opioid therapeutics aimed at managing chronic pain. The company is positioned within the therapeutic devices and broader healthcare services sectors, operating in what can be described as stealth mode.
The business is focused on addressing a critical need in the healthcare market for effective pain management solutions that serve as alternatives to opioids. Its primary market consists of patients and healthcare providers seeking new options for chronic pain treatment. While specific product details are not public, the company's core mission is the development and eventual commercialization of these therapeutic devices.
From a financial perspective, NeuroChronix has secured initial funding to support its research and development efforts. In January 2023, the company raised $20,000 in an Angel investment round. This seed capital has been contributed by investor groups including New Mexico Angels and MIT Alumni Angels of Boston.
Keywords: chronic pain management, non-opioid therapeutics, therapeutic devices, HealthTech, MedTech, pain relief, healthcare services, medical devices, Angel-backed, stealth mode startup, novel therapeutics, alternative pain treatment, healthcare solutions